The short version of SR9009 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Supervised injection sites (SIS), or Drug consumption rooms (DCR), are legally sanctioned, medically supervised facilities designed to address public nuisance associated with drug use and provide a hygienic and stress-free environment for drug consumers. The facilities provide sterile injection equipment, information about drugs and basic health care, treatment referrals, and access to medical staff. Some offer counseling, hygienic and other services of use to itinerant and impoverished individuals. Most programmes prohibit the sale or purchase of illegal drugs. Many require identification cards. Some restrict access to local residents and apply other admission criteria, such as they have to be people who inject substances, but generally in Europe they do not exclude people with substance use disorders who consume their substances through other means. The Netherlands had the first staffed injection room, although they did not operate under explicit legal support until 1996. Instead, the first center where it was legal to inject drugs was in Berne, Switzerland, opened 1986. In 1994, Germany opened its first site. Although, as in the Netherlands they operated in a "gray area", supported by the local authorities and with consent from the police until the Bundestag provided a legal exemption in 2000. In Europe, Luxembourg, Spain and Norway have opened facilities after year 2000. Sydney's Medically Supervised Injecting Center (MSIC) was established in May 2001 as a trial and Vancouver's Insite opened in September 2003.
A YouGov poll for The Times puts Reform UK ahead of the Conservatives for the first time, with Reform on 19% and the Conservatives on 18%; the poll prompts Reform leader Nigel Farage to say his party is "now the opposition to Labour". ITV holds a debate featuring senior figures from the UK's seven main political parties and moderated by Julie Etchingham. 14 June – Data published by the Electoral Commission indicates that Labour raised £351,990 more in donations than the Conservatives during the first week of the general election campaign. BBC Wales sees a series of text messages from the mobile phone of Welsh Conservative Senedd member Laura Anne Jones in which she appears to ask an employee to maximise her expenses claims. Jones is subsequently asked to step back from Wales's Shadow Cabinet as a result of the revelation. A coalition of commercial media and content businesses write to Labour to urge them not to introduce advertising on the BBC, fearing it could have a negative impact on consumers, licence fee payers and creative industries. The Independent Parliamentary Standards Authority clears Douglas Ross of misusing his travel expenses following an investigation. Labour's Rosie Duffield, who is campaigning to be re-elected as MP for Canterbury, says she has withdrawn from hustings events because she does not feel safe; Duffield has previously faced death threats for her stance on sex and gender.
The condition is more common in people with diabetes and may precede diabetes. The mechanism is unclear. Treatment is limited to surgery (typically only in severe cases) and is usually of limited value. Dysglycemia (or dysglycaemia) Abnormal blood sugar levels from any cause which results in disease. A condition resulting from a disorder of blood sugar metabolism. Usually the more specific terms hyperglycemia, hypoglycemia, or others are used instead, and dysglycemia is used only when a firm diagnosis has not yet been made. Dyslipidemia (or dyslipidaemia) Abnormal lipid levels in the blood. Includes levels that are too high (triglycerides, LDLs) and levels that are too low (HDLs). People with insulin resistance and diabetes often have dyslipidemia. Although the cause-and-effect involved is highly complex, the fact that they often coexist and cause problems is clear.
Sources: en.wikipedia.org
The image above shows the interpretation of an antibody panel used in serology to detect antibodies towards the most relevant blood group antigens. Each row represents "reference" or "control" red blood cells of donors which have known antigen compositions and are ABO group O. The + symbol means that the antigen is present on the reference red blood cells, and 0 means it is absent; nt means "not tested". The "result" column to the right displays reactivity when mixing reference red blood cells with plasma from the patient in 3 different phases: room temperature, 37 °C and AHG (with anti-human globulin, by the indirect antiglobulin test).
Three "File" editions reprinted selected content originally published between 1993 and 1996 in Edge issues 1–36. Each volume of "File" covered 12 issues. "Edge presents... The Art Of Videogames" (2007)
An IDF spokesperson stated the attack was "an official declaration of war by Hezbollah" and vowed to "neutralize" the threat. Israel struck southern Lebanon, Beirut, and the Beqaa Valley, with the IDF saying it had killed the head of Hezbollah's intelligence Hussein Makled and Adham Adnan al-Othman, the head of Palestinian Islamic Jihad's armed wing, the Al-Quds Brigades. The Royal Air Force station at Akrotiri, Cyprus, was targeted by a drone strike causing damage to a runway. Another strike on Cyprus led to Greece announcing that it would deploy frigates and F-16s to defend Cyprus from strikes by Iran. The pro-Iran militant group Iraqi Guardians of Blood Brigades claimed responsibility for attacks on the US Victory Base near Baghdad International Airport and Erbil in the Kurdistan Region of Iraq. The Islamic Resistance in Iraq claimed responsibility for 23 drone strikes on US assets in Erbil.
US president Donald Trump stated his belief that the EU would not "push back too much". US treasury secretary Scott Bessent stated that both NATO and Greenland were essential to United States national security. Interior Secretary Doug Burgum argued that Europeans should be "cheering" for the United States to acquire Greenland from Denmark because of it being critical to American and European security. On January, senator Lindsey Graham, a close ally of Trump, urged Europeans to allow the United States to control Greenland and criticised them as being "weak and humorless" on social media. The following month at the 62nd Munich Security Conference, he was asked at a Politico interview what he would say to Europeans who were nervous about Greenland. Graham responded, "Greenland is behind us, but the goal is to get outcomes. Who gives a shit who owns Greenland? I don't." Afterward according to sources reporting to Puck and Berlingske, he met with the Greenlandic and Danish prime ministers, swearing at them often and disrespecting them by yawning loudly and calling the latter "little lady."
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.